pre-production management team in Europe where he will lead the strategy implementation, as well as the European pre-production engineering organization.
“We are pleased to have Iran join the Phillips-Medisize team with nearly 30 years of experience in the drug delivery device segment providing contract design, development and manufacturing services to pharmaceutical companies. Iran brings vast knowledge and leadership experience of complex teams – B2B commercial management and business development, leading the development of operations and pre-production capabilities, scaling up and supporting customer launches of complex drug delivery devices and development,” said Matt Jennings, Chairman and CEO of Phillips-Medisize.
In commenting on his new position, Mr. Bateman said, “I am extremely excited about my appointment and the opportunity this affords me to lead the pre-production activities in Europe while delivering on the existing program commitments. I look forward to expanding the capabilities we offer in Europe, by leveraging our U.S. capabilities to better service our global customers’ needs in Europe. Phillips-Medisize’s capabilities are truly unique and an exception to others in the industry. It is a great pleasure to be a part of this market leading team.”
Mr. Bateman comes to Phillips-Medisize from Tech Group / West Pharmaceutical Services where during his 10 years he held roles encompassing Product Development, NPI and Operations leadership. Prior to joining Tech Group in 2005, Mr. Bateman was Founder and Managing Director of EMS Ltd, a consultancy company to support the industrialization of drug delivery devices. Mr. Bateman spent over 6 years in Consort/Bespak Plc where he held leadership positions spanning account management and business development to program management and site leadership.
Mr. Bateman has an Honours degree in Mechanical Engineering from the University of Portsmouth, UK and a DMS from Warwick Business School, UK.
In addition to Mr. Bateman, Phillips-Medisize has hired several other experienced individuals featuring backgrounds with industry leaders such as Novo Nordisk, Eli Lilly, Quest Diagnostics, Baxter, and Alcon. These investments represent a continued commitment to grow our pre-production services and expertise, and are part of the ongoing strategy to grow both organically and through acquisition.
